Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment
Open Access
- 31 May 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 1181
Abstract
Kidney damage is a well-recognized complication of the antiphospholipid syndrome (APS), either primary or systemic lupus erythematosus (SLE)-associated APS. Kidney involvement in APS involves a variety of manifestations, such as renal artery thrombosis or stenosis, renal vein thrombosis, allograft loss due to thrombosis after kidney transplantation, and injury to the renal microvasculature, also known as APS nephropathy. Biopsy in patients with APS nephropathy includes acute thrombotic microangiopathy lesions and chronic intrarenal vascular lesions such as interlobular fibrous intimal hyperplasia, arterial and arteriolar recanalizing thrombosis, fibrous arterial occlusion, and focal cortical atrophy. The most frequent clinical features are hypertension, microscopic hematuria, proteinuria (ranging from mild to nephritic levels), and renal insufficiency. It is uncertain whether antiphospholipid antibodies or other factors are implicated in the development of APS nephropathy, and whether it is driven mainly by thrombotic or by inflammatory processes. Experimental models and clinical studies of thrombotic microangiopathy lesions implicate activation of the complement cascade, tissue factor, and the mTORC pathway. Currently, the management of APS nephropathy relies on expert opinion, and consensus is lacking. There is limited evidence about the effect of anticoagulants, and their use remains controversial. Treatment approaches in patients with APS nephropathy lesions may include the use of heparin based on its role on complement activation pathway inhibition or the use of intravenous immunoglobulin and/or plasma exchange. Targeted therapies may also be considered based on potential APS nephropathy pathogenetic mechanisms such as B-cell directed therapies, complement inhibition, tissue factor inhibition, mTOR pathway inhibition, or anti-interferon antibodies, but prospective multicenter studies are needed to address their role.Keywords
This publication has 67 references indexed in Scilit:
- Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictionsKidney International, 2013
- The spectrum of renal thrombotic microangiopathy in lupus nephritisArthritis Research & Therapy, 2013
- Imaging For Renovascular DiseaseSeminars in Nephrology, 2011
- Renal Involvement in Primary Antiphospholipid SyndromeClinical Journal of the American Society of Nephrology, 2010
- Association between anti-β2 glycoprotein I antibodies and renal glomerular C4d deposition in lupus nephritis patients with glomerular microthrombosis: a prospective study of 155 casesLupus, 2010
- Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodiesBlood, 2009
- Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 casesArthritis Research & Therapy, 2009
- Prevention of murine antiphospholipid syndrome by BAFF blockadeArthritis & Rheumatism, 2008
- International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)Journal of Thrombosis and Haemostasis, 2006
- Renal vein thrombosis caused by primary antiphospholipid syndromeBritish Journal of Urology, 1994